Robert Bermel, MD

Appointed
2008

Education & Fellowships

Fellowship - Cleveland Clinic
Neuroimmunology (Multiple Sclerosis)
Cleveland, OH
2008

Residency - Cleveland Clinic
Neurology
Cleveland, OH
2007

Internship - Cleveland Clinic
Internal Medicine
Cleveland, OH
2004

Medical Education - State University of New York at Buffalo School of Medicine and Biomedical Sciences
Buffalo, NY
2003

Undergraduate - State University of New York (SUNY) at Buffalo
Buffalo, NY
1999

Professional Highlights

• National Multiple Sclerosis Society Research Grant: "Advanced imaging methods to study recovery from acute optic neuritis"
• Program Committee - American Society of Neuroimaging
• Regular volunteer speaker for the National Multiple Sclerosis Society

Certifications

• Psychiatry and Neurology - Neurology

Specialty Interests

clinical trial research, imaging research, Multiple Sclerosis, Neuroimmunology

Awards & Honors

• 2003   American Society of Neuroimaging William Oldendorf Award for Outstanding Neuroimaging Research. Presented at the ASN Annual Meeting, New Orleans, LA March 7, 2003 for the work entitled: "Gray matter T2 hypointensity predicts longitudinal brain atrophy in MS: effect of interferon beta-1a".
• 2003   American Academy of Neurology Medical Student Prize for Excellence in Neurology. Presented at University at Buffalo School of Medicine commencement May 23, 2003.
• 2003   State University of New York at Buffalo Baccelli Award for Most Outstanding Research. Presented at University at Buffalo School of Medicine commencement May 23, 2003.
• 2001   American Academy of Neurology G. Milton Shy Award in Clinical Neurology. Presented at the AAN Annual Meeting, Philadelphia, PA May 7, 2001 for the work entitled: "Bicaudate ratio as a marker of brain atrophy in multiple sclerosis".

Memberships

• American Academy of Neurology -  member since 2000
• American Medical Association  - member since 1999
• American Society of Neuroimaging - member since 2001. Annual Meeting Program Committee since 2003

See publications for Robert Bermel, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/25/2023, Dr. Bermel has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Bermel receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Sanofi Genzyme
• TG Therapeutics, Inc.
• Novartis International, AG
• EMD Serono, Inc.

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Bermel may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• Qr8 Health, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.